Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 901–1,000 of 1,001
Theocharidou, E., Arvanitakis, K., Koufakis, T., Tsochatzis, E. A., Francque, S., & Germanidis, G. S. (2026) · Drugs · doi:10.1007/s40265-026-02362-6 · Cited by 1
“Fibrosis is the strongest predictor of MASLD-related morbidity and mortality [61].”
Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
Messer, E. K., Petroff, D., Sugimoto, K., Newsome, P. N., Moriyasu, F., Shalimar, Burgio, M. D., Voican, C. S., Vilgrain, V., de Lédinghen, V., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101996 · Cited by 1
Scheiner, B., Dekervel, J., Piscaglia, F., Vitale, A., Kondili, L. A., Procopeț, B., Lazarus, J. V., Buti, M., Zelber‐Sagi, S., & Pinter, M. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101837 · Cited by 1
“48 A second major issue concerns patients with cured HCV cirrhosis.”
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
Self-citationGee, M. F. W., Billin, A. N., Chalfin, D. B., Fonstad, R. K., Devol, E. B., Feld, J. J., Patel, K., & Sanyal, A. J. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102041 · Cited by 1
Self-citationKoning, M., Kovynev, A., Fondevila, M. F., Ruhé, E. J. M., Mommersteeg, M. C., Ramakers, C. R. B., Hutten, B. A., Verwer, B. J., Vlug, M. S., Kuiper, T., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01643-4 · Cited by 1
Xue, F., Liu, J., Chen, J., Li, X., 王思奎, Luo, Y., Zhang, B., Geng, J., Wang, W., Zhao, R., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00243-8 · Cited by 1
Categorization and complication of non-alcoholic fatty liver disease
Alharbi, S. A., Alhayki, A. H., Alghamdi, A. A., Althobaiti, A. S., Alkhalfan, F. F., Muaddi, N. A., Almabouth, M. S., Alfaraj, Z. M., Almajed, M. H., Alkhiri, A. A., et al. (2022) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20223578 · Cited by 1
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.11.010 · Cited by 1
Butt, M. I., Puri, G., Berkman, K., Ryder, S. J., Knowles, J., Shahzad, M. A., Malik, M. A., Shalev, N., & Sexton, J. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem937 · Cited by 2
“Recent findings also support an elevated risk of CKD with progressive fibrosis [26].”
Natural history of nonalcoholic fatty liver disease
Crocombe, D., & Tsochatzis, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00014-5 · Cited by 1
Poynard, T., Deckmyn, O., Pais, R., Aron‐Wisnewsky, J., Peta, V., Bédossa, P., Charlotte, F., Ponnaiah, M., Siksik, J., Siksik, J.-M., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15101253 · Cited by 2
“Because few studies have used the wAUROC, here, we systematically applied an index of fibrosis spectrum variability called DANA (Difference between Advanced and Non-Advanced fibrosis) in patients at risk of MASLD to predict the adjusted bAUROC for the 5-tier CRN stages [17,19,28].”
A Path Toward Improving Nonalcoholic Fatty Liver Disease Care Among Non-hepatologists
Liangpunsakul, S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.014 · Cited by 1
Examining the relationship between non-alcoholic fatty liver disease and hypothyroidism
Teimouri, K., Pakravan, S., & Azadbakht, K. (2022) · Journal of Parathyroid Disease · doi:10.34172/jpd.2022.9148 · Cited by 2
NAFLD et NASH au cours du diabète : données épidémiologiques, cliniques et pronostiques
Béland‐Bonenfant, S., Petit, J., & Vergès, B. L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.011 · Cited by 3
Abordaje de la esteatosis hepática en atención primaria
Bitler, J., Risso, A., Sguiglia, S., Terceiro, D., & Botargues, M. M. (2024) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v27i3.7123 · Cited by 2
Targher, G. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-528 · Cited by 2
“The incidence of cardiovascular events and extra-hepatic cancers was similar across fibrosis stages (4).”
BackgroundMethodResultInfluentialTacke, F., Roeb, E., & Canbay, A. E. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1899-9046 · Cited by 1
NAFLD in Indians: A Myopic Yet Alarming Perspective
Singh, S. P., & Anirvan, P. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.016 · Cited by 1
Biswas, S., & Shalimar, S. (2023) · JGH Open · doi:10.1002/jgh3.12996 · Cited by 1
Behari, J. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08270-7 · Cited by 2
“Compared with patients with none—mild liver fibrosis (F0-2), those with advanced fibrosis ( ≥ F3) or cirrhosis (F4) have a progressively higher risk of liver-related complications [1].”
Yoon, E. L., & Jun, D. W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0360 · Cited by 1
Hepatic Fibrosis Risk Assessment in Primary Care: Opportunities and Challenges
Fuller, S. R., & Schreiner, A. D. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08498-3 · Cited by 1
“Advanced fibrosis in MASLD is the single best predictor of future severe liver outcomes including cirrhosis, complications of cirrhosis, and hepatocellular carcinoma [3].”
Lui, J., Kweon, Y., & Elsaid, M. I. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70461 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
Crespo, J., & Iruzubieta, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176637 · Cited by 1
“…stage—approximately 0.32, 0.89, and 1.76 deaths per 100 person-years across early fibrosis (F0–F2), bridging fibrosis (F3), and cirrhosis (F4) [5]—and a separate long-term histologic cohort confirmed that fibrosis stage, rather than steatosis or inflammation, is the feature that governs…”
InfluentialRIP, a one-dimensional material response code. Volume I. User's guide. Final report
Fisher, R. H., Lane, G., & Cecil, R. (1972) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
TREMBLAY, J.-F. (2004) · Chemical & Engineering News · doi:10.1021/cen-v082n017.p014
Lee, C., Lui, D. T. W., & Lam, K. S. L. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13765
“The recent study by Sanyal et al.(2), published in the New England Journal of Medicine, was the first prospective”
BackgroundResultInfluentialPan-PPAR-Agonist bei nicht alkoholischer Steatohepatitis
Klose, G. (2022) · Gastro-News · doi:10.1007/s15036-022-2455-9
NAFLD: Mortalität und Komplikationen steigen mit zunehmender Fibrose an
(2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1687-7093
Ananthakrishnan, A. N. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.03.005
Causes and Effects of Obesity on Health of Children in Australia
Raziani, A. K., Singhal, H. M., & Bleich, I. Z. (2022) · Journal of Medicine Nursing & Public Health · doi:10.53819/81018102t5138
Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
Yoshiji, H., Namisaki, T., Kaji, K., & Francque, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_19
Screening for advanced liver fibrosis in overweight and obese patients with NAFLD
Stefan, N. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.29
Nakamura, A., Watanabe, S., Yoshimura, T., Ishida, N., Fuchigami, A., Sato, T., Ichikawa, T., Okuyama, K., Inoue, M., & Asakura, H. (2023) · Kanzo · doi:10.2957/kanzo.64.44
Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences
Younossi, Z. M., & Henry, L. L. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/22-00150 · Cited by 3
Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique
Brissot, P., & Buffet, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.014 · Cited by 3
Jung, H. N., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0038
“Finally, the authors indicated that patients who meet more criteria for metabolic dysfunction may have a higher mortality risk [19].”
BackgroundNASH et chirurgie de l’obésité
Leray, M., Lassailly, G., & Pattou, F. N. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.12.002 · Cited by 1
Towards omics-based risk assessment in NAFLD
Ajmera, V. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00772-4
Data from A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · doi:10.1158/2159-8290.c.6602824.v1
Data from A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · doi:10.1158/2159-8290.c.6602824
Non-Alcoholic Fatty Liver Disease: Current Concepts of a Silent, but Potentially Reversible Disorder
Gómez, M. I. (2023) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2023.19.556019
Personalisierte Therapie der metabolisch assoziierten Fettlebererkrankung
Clusmann, J., Schneider, K. M., Koop, P., Plauth, M., & Schneider, C. V. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00701-7
Adipositas und NAFLD: Assoziation oder Auslöser?
Roeb, E., & Tacke, F. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2059-9049
Noninvasive disease severity assessment in nonalcoholic fatty liver disease
Huang, J. (2023) · Advances in digestive medicine · doi:10.1002/aid2.13375
“There is a higher risk of mortality associated with a higher stage of fibrosis in NAFLD.10,11 Moreover, the risk of liver-related mortality increased on an exponential rather than linear scale with an increase in fibrosis stage.12 Liver biopsy remains an expensive and invasive procedure associated with potential compl…”
BackgroundPaik, J. M., Deavila, L., & Younossi, Z. M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.06.017
Cholesterol-associated Locus EHBP1 Protects against NASH FibrosisPreprint
Ma, F., Longo, M., Huang, X., Meroni, M., Prakash, S., Paolini, E., Bhattacharya, D., Wang, S., Wang, X., Mughal, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.08.548218 · Cited by 1
NAFLD: Diagnostics and New Nomenclature
Kanagalingam, G., & Sanyal, A. J. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.07.003
Self-citationZenovia, S., Muzica, C. M., & Dimache, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_10
Artificial intelligence in prediction of steatosis and fibrosis of nonalcoholic fatty liver disease
Wong, G. L., Yuen, P. C., Ma, A. J., Chan, A. W. H., Leung, H. H. W., & Wong, V. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99136-0.00003-9
Non-invasive Tests of Fibrosis: Does One Size Fit All?
James, M., & Alazawi, W. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08094-x
Козак, О. А., & Господарський, І. Я. (2023) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2023.v.i3.14003
Awatara, P. I. D., Poetri, L. N., Fajar, J. K., & MUSTIKA, S. (2023) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2023-97079
Non-Alcoholic Fatty Liver Disease : Insights into Alcohol Consumption, Genetics, and Proteomics
Blomdahl, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180752923
Kim, K., & Park, J. Y. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-501 · Cited by 2
“advanced fibrosis (incidence of 0.34 per 100 person-years) (8).”
InfluentialHemodynamic Changes in Chronic Liver Disease
Jo, S., & Park, K. (2023) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2023.124
Muñoz, S., Jiménez-Masip, A., & Pericàs, J. M. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-563
“Liver fibrosis has been extensively proven as the main predictor of disease progression and complications in MASLD, including cardiovascular events, renal complications, non-hepatic neoplasms and liver events (3).”
Comorbid Conditions of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_6
Esteban, J. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-48949-5_65
Usefulness of long-term administration of SGLT2 inhibitors in patients with MASLD and diabetes
Ishii, K., Kawanaka, M., Oda, S., Kimura, M., Kawada, M., Tanikawa, T., Urata, N., Nishino, K., Suehiro, M., Haruma, K., et al. (2024) · Kanzo · doi:10.2957/kanzo.65.111
Kalligeros, M., & Tsochatzis, E. A. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-654 · Cited by 1
“The progression of MASLD to advanced fibrosis, marked by excessive extracellular matrix deposition and scar tissue formation, is a critical stage in MASLD natural history that significantly increases the risk of liver-related complications mortality (3).”
Jia, Y., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Yi, L., & Liao, X. (2023) · Figshare · doi:10.6084/m9.figshare.24416199
Krishna, R. V. V. S. S., & Sheriff, F. M. A. (2024) · AIP conference proceedings · doi:10.1063/5.0197574
Awan, S. A., Wibawa, I. D. N., Jawi, I. M., Pinatih, G. N. I., & Mahendra, A. N. (2023) · Bali Medical Journal · doi:10.15562/bmj.v12i2.4483
MASLD biomarkers: Are we facing a new era?
Maya‐Miles, D., Ampuero, J., Aguado, D. M., Conthe, A., & Gallego‐Durán, R. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2024.02.002
Yu, W., Zhang, C., Li, S., Zhang, J., Zhang, X., Han, G., Liu, F., Shao, H., Ling, P., & Fang, B. (2024) · Research Square · doi:10.21203/rs.3.rs-4484580/v1
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease
Friedman, S. L. (2024) · Med · doi:10.1016/j.medj.2024.04.007
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
Song, D. S. (2024) · Gut and Liver · doi:10.5009/gnl240200 · Cited by 1
Sena, E., Tacke, F., Anstee, Q. M., Prospero, N. A. D., Kjær, M. S., Muñoz, S., Rivera‐Esteban, J., Jiménez-Masip, A., Bañales, J. M., Martínez-Gómez, M., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00560-5
Hepatologist Consultation in Low-Risk MASLD
Schubach, A., Carr, R. M., & Abdelmalek, M. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmclde2404875
СТЕАТОТИЧНА ХВОРОБА ПЕЧІНКИ: МОЖЛИВОСТІ ДІАГНОСТИКИ В ЗАГАЛЬНОЛІКАРСЬКІЙ ПРАКТИЦІ
Іваницький, І. О., Ждан, В. Н., Бабаніна, М. Ю., & Ткаченко, М. В. (2024) · Перспективи та інновації науки · doi:10.52058/2786-4952-2024-8(42)-1051-1062
Stratégie diagnostique des hépatopathies chroniques
Canivet, C. M. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-78562-7.00006-0
Hajihosseini, M., Talarico, F., Zhao, C., Campbell, S., Udenze, D., Bastani, N. H., Ahmed, M., Ghasemi, E., Tonoyan, L., Guirguis, M. S., et al. (2024) · medRxiv · doi:10.1101/2024.10.17.24315623
“Inflammation and fibrosis are closely interlinked, as evidenced in many chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD, a.k.a MASLD) (1,2), non-alcoholic steatohepatitis (NASH, a.k.a MASH) (3), and alcohol-associated liver diseases (ALD) (4).”
BackgroundRayginia, T. P., Keerthana, C. K., Aiswarya, S. U. D., Shifana, S. C., Jannet, S., Varma, S. S., Maria, J. P., Swetha, M., Retnakumari, A. P., Nath, L. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.622394
Association of Comorbidity Duration with the Occurrence and Prognosis of Steatotic Liver Disease
Sang, H., Lim, J. H., & Kim, H. I. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08723-z
“Previous studies have reported that metabolic risk factors such as diabetes mellitus (DM), hypertension (HTN), and dyslipidemia (DL) increased not only the occurrence of SLD but also the associated progression of liver fibrosis, cardiovascular disease, occurrence of malignant tumor, or death [2, 3].”
Cirrhose métabolique : une entité en plein essor
Ratziu, V. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.11.012
Tang, X., Wang, F., Gao, Y., Liu, Y., Zhao, S.-L., Lu, J. L., Qin, J., & Zhang, B. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5061164
Histopathology of MASLD: Insights into Liver Tissue Changes
Francque, S., & Driessen, A. L. C. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_6 · Cited by 2
Magnetic Resonance Imaging Quantification of Steatosis, Iron, and Fibrosis in Chronic Liver Disease
Aguado, D. M., & Martí‐Bonmatí, L. (2025) · Neuromethods · doi:10.1007/978-1-0716-4354-9_3
Shi, Q., Ran, S., Song, L., Yang, H., Wang, W., Liu, H., & Liu, Q. (2025) · PubMed Central · doi:10.12122/j.issn.1673-4254.2025.01.15
Kim, G., Jang, H., Kim, M. Y., Park, J. G., Cho, E.-Y., Jeong, J. Y., Jeong, S., Han, S. K., Park, S. Y., Kim, S. G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5134438
Васильевна, Ц. О., Тимощенко, О. В., Latyntseva, L. D., Викторовна, А. Е., & Aleksandrova, O. V. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-14-25
“…снижение индекса массы тела (ИМТ) с 29,6 [25,5; 33,1] до 27,1 [22,2; 31,0] кг/м 2 , р=0,047; окружности талии (ОТ) — с 99,5 [91,5; 104,5] до 96,5 [89,5; 100,5] см, р=0,044 и процентного содержания жира в организме по данным биоимпедансометрии — с 22,3 [19,5; 25,6] до 20,3 [17,4; 23,9]%, р=0,022.”
Bekbossynova, M. S., Myrzakhmetova, G., Seitkasym, S., Sailybayeva, A., Khamitov, S., Daniyarova, G., & Akzholova, K. (2025) · BULLETIN OF SURGERY IN KAZAKHSTAN · doi:10.35805/bsk2025i004
Approche de la stéatose hépatique en clinique: Diagnostic, prise en charge et nomenclature proposée
Szilagyi, A., & Hilzenrat, N. (2025) · Canadian Family Physician · doi:10.46747/cfp.7104e56
“De plus, elle pose un risque de maladie hépatique progressive 30 .”
Approach to steatotic liver disease in the office: Diagnosis, management, and proposed nomenclature
Szilagyi, A., & Hilzenrat, N. (2025) · Canadian Family Physician · doi:10.46747/cfp.7104249 · Cited by 2
“30 Most cases of MASLD are associated with obesity or overweight status.”
The Heated Race Against MASH: Will the Scope, Scalpel, or Medication Prevail?
Samala, N. R., & Al‐Haddad, M. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.023
Reiberger, T., Dominik, N., & Trauner, M. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.01.047 · Cited by 1
SMYD2 inhibitors have no effect in improving non-alcoholic steatohepatitis in mice
Yang, L., Zhuo, S., Zhu, X., Zhang, X., Wang, Z., & Chen, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1480453 · Cited by 1
“Ultimately, patients with NASH and advanced fi brosis may develop end-stage complications, including cirrhosis, portal hypertension, or hepatocellular carcinoma (HCC), all of which are associated with substantially worse prognosis (7 – 11).”
The Role of Clinical Chemistry in Early Detection of Liver Disorders
Abd, F. F., Jabar, Z. A. H., Kadhim, A. J. A. A., Hussein, S. M., & Abbas, Z. O. (2025) · Bright Sky Publications eBooks · doi:10.62906/bs.book.390
AGE-RELATED FEATURES OF LIVER CHANGES DURING INTERMITTENT FASTING (LITERATURE REVIEW)
Kryvozub, D., Riabenko, T. V., & Ponyrko, A. (2025) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2025;13(2):352-363
Meron, M. K., Hornik‐Lurie, T., Rotman‐Pikielny, P., Yakov, G. B., Twig, G., & Karpati, T. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003605 · Cited by 2
Effects of type 2 diabetes and weight loss on serum CK-18 in MASLD patients
Zhao, S., & Gan, J. (2025) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2025.05.001
Community prevalence of advanced liver fibrosis in Type 2 diabetes—How big is the challenge?
Abeysekera, K. W. M., & Brennan, P. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20113
“Importantly, fibrosis is the only histological feature which is known to determine the risk of liver-related events, with progressive stages of fibrosis conferring the highest risk of adverse outcomes [6, 7].”
Kapoor, A., & Kapur, A. (2025) · International Journal of Gastroenterology · doi:10.11648/j.ijg.20250901.110
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.